Race Oncology Gains Ethics Approval for HARNESS-1 Phase 1a/b RC220 Lung Cancer Trial.
Race Oncology Limited (ASX: RAC) has secured human ethics approval to commence its HARNESS-1 Phase 1a/b clinical trial assessing RC220 in combination with osimertinib for patients with EGFR-mutated non-small cell lung cancer. Approval from the St Vincents Hospital Melbourne HREC enables Monash Health to begin enrolling patients once final site activation steps are completed, anticipated between late Q4 2025 and early Q1 2026. The multi-centre trial will use ctDNA to identify suitable candidates and will initially focus on dose escalation to establish the maximum tolerated dose of RC220.
After completing Phase 1a, the study will progress to a randomised Phase 1b dose-expansion stage involving 40 participants. This phase will evaluate safety, pharmacokinetics and clinical outcomes such as progression-free survival, overall survival and ctDNA response. With multiple sites preparing for activation, this approval marks a key milestone for Race Oncology as it advances RC220 to address emerging resistance pathways in EGFR-mutated lung cancer.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au.au
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Race Oncology Gains Ethics Approval for HARNESS-1 Phase 1a/b RC220 Lung Cancer Trial.
Race Oncology Limited (ASX: RAC) has secured human ethics approval to commence its HARNESS-1 Phase 1a/b clinical trial assessing RC220 in combination with osimertinib for patients with EGFR-mutated non-small cell lung cancer. Approval from the St Vincents Hospital Melbourne HREC enables Monash Health to begin enrolling patients once final site activation steps are completed, anticipated between late Q4 2025 and early Q1 2026. The multi-centre trial will use ctDNA to identify suitable candidates and will initially focus on dose escalation to establish the maximum tolerated dose of RC220.
After completing Phase 1a, the study will progress to a randomised Phase 1b dose-expansion stage involving 40 participants. This phase will evaluate safety, pharmacokinetics and clinical outcomes such as progression-free survival, overall survival and ctDNA response. With multiple sites preparing for activation, this approval marks a key milestone for Race Oncology as it advances RC220 to address emerging resistance pathways in EGFR-mutated lung cancer.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au.au